DNA vs PHAT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 23, 2026

DNA

58.0
AI Score
VS
DNA Wins

PHAT

51.2
AI Score

Investment Advisor Scores

DNA

58score
Recommendation
HOLD

PHAT

51score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric DNA PHAT Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -49.1% 104.4% PHAT
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 58.0/100 51.2/100 DNA
Profit Margin -201.0% -76.8% PHAT
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

DNA 1M: +75.7% · 3M: +22.2% PHAT 1M: -25.3% · 3M: -39.2%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 75

RSI (14): 74.6 · Price: $12.35

PHAT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -13.5%), weak momentum, RSI 33

RSI (14): 32.7 · Price: $6.92

Fundamentals Snapshot

Metric DNA PHAT
Market Cap — —
Forward P/E -4.3 6.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.5% 0.9%
Gross Margin 0.7% 0.8%
Operating Margin -2.8% -0.1%
EPS -5.19 -1.21
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.